Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc., a prominent player in the life sciences sector, is revolutionizing the field of proteomics. The company is known for its development and commercialization of the Proteograph Product Suite, an integrated solution designed to unlock deep, unbiased biological information. The suite comprises consumables, automation instrumentation, and software that enable comprehensive proteomic profiling and sample analysis, providing researchers with a detailed view of the proteome.
Seer's technology is built around proprietary engineered nanoparticles, which offer unmatched depth and scale in proteomic studies. This innovative approach allows for the detection of over 6,000 proteins and more than 55,000 peptide IDs in complex samples, such as plasma. The Proteograph Product Suite is designed for ease of use, with features like minimal hands-on time and fully automated workflows, making it accessible to a wide range of research labs.
The company primarily targets academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies, offering its products for non-diagnostic and non-clinical purposes. Seer has established significant collaborations with industry leaders like Discovery Life Sciences, Bruker Scientific LLC, and Thermo Electron North America LLC, enhancing its market reach and technological capabilities.
Recently, Seer has made headlines through its partnership with Panome Bio to integrate deep, unbiased proteomics with metabolomics, aiming to accelerate research in biomarker discovery and drug development. The collaboration is expected to facilitate groundbreaking studies with robust pathway analyses, significantly advancing the understanding of biology and disease.
In another noteworthy development, Seer announced a major study published in Nature Communications, conducted in collaboration with Weill Cornell Medicine. This research showcased Seer's Proteograph workflow's potential to unveil novel proteogenomic insights, linking genetic variation with protein abundance at peptide level resolution. This study is a testament to Seer's commitment to advancing multi-omics research and enhancing precision medicine.
Seer's financial outlook remains optimistic despite macroeconomic challenges. The company continues to drive the adoption of its Proteograph Product Suite by expanding its Technology Access Center and increasing its commercial reach. As more customer data and third-party publications highlight the power of Seer's technology, the company anticipates growing adoption and impact in the scientific community.
In summary, Seer, Inc. is at the forefront of proteomics, offering transformative solutions that provide unparalleled insights into the proteome, thus paving the way for significant advancements in biological research and precision medicine.
Seer Appoints New Chief Commercial Officer
Seer, Inc. (Nasdaq: SEER) announced the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Thomas joins Seer with over 20 years of sales experience in the life sciences sector, previously serving at Singular Genomics and Illumina. CEO Omid Farokhzad expressed enthusiasm for Thomas's leadership as the company accelerates its commercial efforts following the launch of the Proteograph Product Suite, designed to enhance access to proteomic analysis.
Seer, Inc. (Nasdaq: SEER) announced a study published in PNAS showcasing their Proteograph Product Suite's superior performance in deep proteomics. The study revealed significant advancements in precision and throughput, achieving a median depth of coverage improvement of tenfold, 2x precision enhancement, and 2.5x more protein identifications compared to conventional methods. These findings establish the Proteograph as a leading tool for unbiased proteomics studies, vital for understanding the proteome's role in precision medicine.
Seer, Inc. (Nasdaq: SEER) reported a significant increase in revenue for the full year 2021, totaling $6.6 million, driven by the successful launch of the Proteograph Product Suite. The fourth quarter alone saw revenue of $3.1 million, up from $336 thousand in Q4 2020. However, the company faced a net loss of $19.7 million in the fourth quarter and $71.2 million for the full year. For 2022, Seer anticipates revenue of $14.0 million to $16.0 million while increasing investments in commercial and R&D activities.
Seer, a life sciences company specializing in proteomics, has announced its virtual participation in the Cowen 42nd Annual Health Care Conference scheduled for March 8, 2022. The company's management will engage in a fireside chat at 11:50 a.m. Pacific Time. Interested investors can access a live webcast on Seer’s investor website, with an archived replay available afterward. Seer’s Proteograph Product Suite enables deep proteomic analysis efficiently and is designed for research use only, aiming to enhance laboratory capabilities.
Seer Inc. (NASDAQ: SEER) will release its financial results for Q4 and full year 2021 on February 28, 2022, after market close. A conference call with management will follow at 1:30 PM PT / 4:30 PM ET, available via a live webcast on Seer's investor website. Seer specializes in proteomics, offering the Proteograph Product Suite, which comprises engineered nanoparticles and software for comprehensive proteomic analysis. The suite aims to enhance research efficiency, though it is not intended for diagnostic use.
Seer Inc. (NASDAQ: SEER) has officially launched the Proteograph Product Suite, which promises revolutionary advancements in proteomics, akin to next-generation sequencing in genomics. The suite employs proprietary engineered nanoparticles, enabling rapid and unbiased proteomics analysis. Seer has secured multiple orders for this product and initiated its Centers of Excellence program, partnering with leading service providers globally to facilitate the technology's adoption. Key partners include Biodesix and Discovery Life Sciences, enhancing service accessibility in major geographies.
Seer Inc. (NASDAQ: SEER), SCIEX, and Discovery Life Sciences have formed the Proteogenomics Consortium to enhance proteomics analysis for genomics research. This collaboration aims to analyze over 1 billion peptides annually, enabling the discovery of new protein variants and biomarkers. The Proteograph Product Suite and SCIEX ZenoTOF 7600 will provide deep, unbiased proteomics capabilities. The consortium is positioned to accelerate research in human health and disease, significantly expanding proteomic studies across various cohorts.
Seer Inc. (NASDAQ: SEER) has announced the broad commercial release of its Proteograph Product Suite, which facilitates unbiased and rapid proteomics. The product suite has garnered multiple orders and includes engineered nanoparticles, automated instrumentation, and software for deep proteomics studies. Seer's new Centers of Excellence program aims to accelerate the adoption of this technology by partnering with leading service providers worldwide. These developments position Seer as a leader in innovative proteomics solutions, enhancing research capabilities across various regions.
Seer, Inc. (Nasdaq: SEER) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. The management team is scheduled to present at 8:15 a.m. Pacific Time and will hold a Q&A session. A live webcast will be available on Seer's investor website, with an archived replay accessible afterward.
Seer specializes in developing products for proteomic analysis, including the Proteograph™ Product Suite, designed for deep and unbiased analysis in a streamlined manner. This product is intended for research use only.
Seer, Inc. (Nasdaq: SEER) has appointed Meeta Gulyani to its Board of Directors. Gulyani, currently Executive Vice President at Merck KGaA, brings extensive experience in life sciences. Her leadership is expected to support Seer's mission in proteomics, which aims to unlock new insights in healthcare. Gulyani has held significant roles at Roche and possesses a strong background in strategy, business development, and transformation. Seer's Proteograph Product Suite is at the forefront of proteomic analysis, enhancing research capabilities in various laboratories.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is Seer, Inc. known for?
What does the Proteograph Product Suite include?
Who are Seer's primary customers?
What recent collaborations has Seer announced?
What are the benefits of Seer's proprietary engineered nanoparticles?
What was the focus of Seer's recent study published in Nature Communications?
What is Seer's strategy to drive adoption of its technology?
Is the Proteograph Product Suite intended for diagnostic use?
Where is Seer, Inc. headquartered?
What potential does Seer see in its technology?
